Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina.

Scolnik M, Scaglioni V, Pons-Estel GJ, Soriano ER.

Lupus. 2019 Aug;28(9):1167-1173. doi: 10.1177/0961203319861687. Epub 2019 Jul 12.

PMID:
31299882
2.

Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort.

Pimentel-Quiroz VR, Ugarte-Gil MF, Harvey GB, Wojdyla D, Pons-Estel GJ, Quintana R, Esposto A, García MA, Catoggio LJ, Cardiel MH, Barile LA, Amigo MC, Sato EI, Bonfa E, Borba E, Lavras Costallat LT, Neira OJ, Massardo L, Guibert-Toledano M, Chacón-Díaz R, Alarcón GS, Pons-Estel BA.

Lupus. 2019 Aug;28(9):1101-1110. doi: 10.1177/0961203319860579. Epub 2019 Jul 10.

PMID:
31291843
3.

Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort.

Ugarte-Gil MF, Pons-Estel GJ, Vila LM, McGwin G, Alarcón GS.

RMD Open. 2019 May 23;5(1):e000955. doi: 10.1136/rmdopen-2019-000955. eCollection 2019.

4.

Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort.

Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Quintana R, Gómez-Puerta JA, Catoggio LJ, Alvarellos A, Saurit V, Borba E, Sato E, Costallat L, Da Silva NA, Iglesias-Gamarra A, Neira O, Reyes-Llerena G, Cardiel MH, Amigo MC, Acevedo-Vásquez E, Esteva-Spinetti MH, Alarcón GS, Pons-Estel BA.

J Rheumatol. 2019 Oct;46(10):1299-1308. doi: 10.3899/jrheum.180433. Epub 2019 Mar 1.

PMID:
30824636
5.

Is Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et al.

Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Pons-Estel BA, Alarcón GS.

Arthritis Rheumatol. 2018 Dec;70(12):2098-2099. doi: 10.1002/art.40694. Epub 2018 Sep 24. No abstract available.

PMID:
30120903
6.

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR).

Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, Criniti JM, Vásquez G, Massardo L, Duarte M, Barile-Fabris LA, García MA, Amigo MC, Espada G, Catoggio LJ, Sato EI, Levy RA, Acevedo Vásquez EM, Chacón-Díaz R, Galarza-Maldonado CM, Iglesias Gamarra AJ, Molina JF, Neira O, Silva CA, Vargas Peña A, Gómez-Puerta JA, Scolnik M, Pons-Estel GJ, Ugolini-Lopes MR, Savio V, Drenkard C, Alvarellos AJ, Ugarte-Gil MF, Babini A, Cavalcanti A, Cardoso Linhares FA, Haye Salinas MJ, Fuentes-Silva YJ, Montandon de Oliveira E Silva AC, Eraso Garnica RM, Herrera Uribe S, Gómez-Martín D, Robaina Sevrini R, Quintana RM, Gordon S, Fragoso-Loyo H, Rosario V, Saurit V, Appenzeller S, Dos Reis Neto ET, Cieza J, González Naranjo LA, González Bello YC, Collado MV, Sarano J, Retamozo S, Sattler ME, Gamboa-Cárdenas RV, Cairoli E, Conti SM, Amezcua-Guerra LM, Silveira LH, Borba EF, Pera MA, Alba Moreyra PB, Arturi V, Berbotto GA, Gerling C, Gobbi CA, Gervasoni VL, Scherbarth HR, Brenol JCT, Cavalcanti F, Costallat LTL, Da Silva NA, Monticielo OA, Seguro LPC, Xavier RM, Llanos C, Montúfar Guardado RA, Garcia de la Torre I, Pineda C, Portela Hernández M, Danza A, Guibert-Toledano M, Reyes GL, Acosta Colman MI, Aquino AM, Mora-Trujillo CS, Muñoz-Louis R, García Valladares I, Orozco MC, Burgos PI, Betancur GV, Alarcón GS; Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR).

Ann Rheum Dis. 2018 Nov;77(11):1549-1557. doi: 10.1136/annrheumdis-2018-213512. Epub 2018 Jul 25.

7.

A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients.

Pons-Estel GJ, Quintana R, Alarcón GS, Sacnún M, Ugarte-Gil MF, Pons-Estel BA; GLADEL.

Lupus. 2018 Sep;27(10):1753-1754. doi: 10.1177/0961203318776104. Epub 2018 May 15. No abstract available.

PMID:
29764291
8.

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):134-141. doi: 10.1002/acr.23584.

PMID:
29669399
9.

Remission or low disease activity as a target in systemic lupus erythematosus.

Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Pons-Estel BA, Alarcón GS; GLADEL.

Ann Rheum Dis. 2019 Jan;78(1):e3. doi: 10.1136/annrheumdis-2017-212876. Epub 2018 Jan 8. No abstract available.

PMID:
29311147
10.

Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).

Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ, Drenkard C, Sarano J, Berbotto GA, Borba EF, Sato EI, Tavares Brenol JC, Uribe O, Ramirez Gómez LA, Guibert-Toledano M, Massardo L, Cardiel MH, Silveira LH, Chacón-Diaz R, Alarcón GS, Pons-Estel BA; GLADEL.

Ann Rheum Dis. 2017 Dec;76(12):2071-2074. doi: 10.1136/annrheumdis-2017-211814. Epub 2017 Sep 22.

PMID:
28939626
11.

Epidemiology of systemic lupus erythematosus.

Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS.

Expert Rev Clin Immunol. 2017 Aug;13(8):799-814. doi: 10.1080/1744666X.2017.1327352. Epub 2017 May 16. Review.

PMID:
28471259
12.

Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort.

Pimentel-Quiroz VR, Ugarte-Gil MF, Pons-Estel GJ, Soriano ER, Saurit V, Sato EI, Lavras Costallat LT, Molina JF, Iglesias-Gamarra A, Reyes-Llerena G, Neira OJ, Barile LA, Silveira LH, Segami MI, Chacón-Díaz R, Wojdyla D, Alarcón GS, Pons-Estel BA.

Semin Arthritis Rheum. 2017 Oct;47(2):199-203. doi: 10.1016/j.semarthrit.2017.01.012. Epub 2017 Feb 2.

PMID:
28291583
13.

The antiphospholipid syndrome in patients with systemic lupus erythematosus.

Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A.

J Autoimmun. 2017 Jan;76:10-20. doi: 10.1016/j.jaut.2016.10.004. Epub 2016 Oct 21. Review.

PMID:
27776934
14.

Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort.

Pons-Estel GJ, Aspey LD, Bao G, Pons-Estel BA, Wojdyla D, Saurit V, Alvarellos A, Caeiro F, Haye Salinas MJ, Sato EI, Soriano ER, Costallat LT, Neira O, Iglesias-Gamarra A, Reyes-Llerena G, Cardiel MH, Acevedo-Vásquez EM, Chacón-Díaz R, Drenkard C.

Lupus. 2017 Jan;26(1):73-83. Epub 2016 May 26.

PMID:
27230554
15.

Treatment Algorithms for Patients with Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al.

González LA, Pons Estel GJ, Burgos PI, Alarcón GS.

Arthritis Care Res (Hoboken). 2016 Sep;68(9):1385. doi: 10.1002/acr.22849. Epub 2016 Jul 28. No abstract available.

16.

Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort.

González-Naranjo LA, Betancur OM, Alarcón GS, Ugarte-Gil MF, Jaramillo-Arroyave D, Wojdyla D, Pons-Estel GJ, Rondón-Herrera F, Vásquez-Duque GM, Quintana-López G, Da Silva NA, Tavares Brenol JC, Reyes-Llerena G, Pascual-Ramos V, Amigo MC, Massardo L, Alfaro-Lozano J, Segami MI, Esteva-Spinetti MH, Iglesias-Gamarra A, Pons-Estel BA.

Semin Arthritis Rheum. 2016 Jun;45(6):675-83. doi: 10.1016/j.semarthrit.2015.11.003. Epub 2015 Nov 12.

PMID:
26698222
17.

Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary.

Ugarte-Gil MF, Pons-Estel GJ, Molineros J, Wojdyla D, McGwin G Jr, Nath SK, Pons-Estel BA, Alarcón-Riquelme M, Alarcón GS.

Rheumatology (Oxford). 2016 Mar;55(3):436-40. doi: 10.1093/rheumatology/kev280. Epub 2015 Sep 27.

18.

The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.

Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D; APS ACTION.

Lupus. 2015 Aug;24(9):980-4. doi: 10.1177/0961203315572714. Epub 2015 Feb 18. Review.

PMID:
25697769
19.

Lupus in Latin-American patients: lessons from the GLADEL cohort.

Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, Massardo L, Molina-Restrepo JF, Toledano MG, Barile-Fabris LA, Amigo MC, Acevedo-Vásquez EM, Abadi I, Wojdyla D, Alarcón-Riquelme ME, Alarcón GS, Pons-Estel BA; GLADEL.

Lupus. 2015 May;24(6):536-45. doi: 10.1177/0961203314567753. Epub 2015 Feb 18. Review.

PMID:
25697768
20.

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Ugarte-Gil MF, Acevedo-Vásquez E, Alarcón GS, Pastor-Asurza CA, Alfaro-Lozano JL, Cucho-Venegas JM, Segami MI, Wojdyla D, Soriano ER, Drenkard C, Brenol JC, de Oliveira e Silva Montandon AC, Costallat LT, Massardo L, Molina-Restrepo JF, Guibert-Toledano M, Silveira LH, Amigo MC, Barile-Fabris LA, Chacón-Díaz R, Esteva-Spinetti MH, Pons-Estel GJ, McGwin G Jr, Pons-Estel BA; GLADEL.

Ann Rheum Dis. 2015 Jun;74(6):1019-23. doi: 10.1136/annrheumdis-2013-204620. Epub 2014 Feb 13.

PMID:
24525909
21.

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, Buonaiuto V, Jacobsen S, Zeher MM, Tarr T, Tincani A, Taglietti M, Theodossiades G, Nomikou E, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Fernández-Nebro A, Haro M, Amoura Z, Miyara M, Tektonidou M, Espinosa G, Bertolaccini ML, Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies).

Ann Rheum Dis. 2015 Jun;74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838. Epub 2014 Jan 24.

22.

Renal involvement in antiphospholipid syndrome.

Pons-Estel GJ, Cervera R.

Curr Rheumatol Rep. 2014 Feb;16(2):397. doi: 10.1007/s11926-013-0397-0. Review.

PMID:
24357443
23.

The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary.

Pons-Estel GJ, Wojdyla D, McGwin G Jr, Magder LS, Petri MA, Pons-Estel BA; Grupo Latino Americano De Estudio del Lupus (GLADEL), Alarcón GS; LUMINA cohort.

Lupus. 2014;23(1):3-9. doi: 10.1177/0961203313512883. Epub 2013 Nov 27.

PMID:
24285098
24.

Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature.

Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D.

Arthritis Care Res (Hoboken). 2013 Nov;65(11):1869-73.

25.

Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort.

Pons-Estel GJ, Alarcón GS, Burgos PI, Hachuel L, Boggio G, Wojdyla D, Nieto R, Alvarellos A, Catoggio LJ, Guibert-Toledano M, Sarano J, Massardo L, Vásquez GM, Iglesias-Gamarra A, Lavras Costallat LT, Da Silva NA, Alfaro JL, Abadi I, Segami MI, Huerta G, Cardiel MH, Pons-Estel BA; Grupo Latino Americano de Estudio de Lupus (GLADEL).

Lupus. 2013 Aug;22(9):899-907. doi: 10.1177/0961203313496339. Epub 2013 Jul 15.

26.

Lupus in Hispanics: a matter of serious concern.

Pons-Estel GJ, Alarcón GS.

Cleve Clin J Med. 2012 Dec;79(12):824-34. doi: 10.3949/ccjm.79a.12048. Review.

PMID:
23208987
27.

The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Pons-Estel GJ, Saurit V, Alarcón GS, Hachuel L, Boggio G, Wojdyla D, Alfaro-Lozano JL, de la Torre IG, Massardo L, Esteva-Spinetti MH, Guibert-Toledano M, Gómez LA, Costallat LT, Del Pozo MJ, Silveira LH, Cavalcanti F, Pons-Estel BA.

Lupus. 2012 Nov;21(13):1397-404. doi: 10.1177/0961203312458465. Epub 2012 Aug 31.

28.

Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort.

Pons-Estel GJ, Alarcón GS, Hachuel L, Boggio G, Wojdyla D, Pascual-Ramos V, Soriano ER, Saurit V, Cavalcanti FS, Guzman RA, Guibert-Toledano M, Sauza Del Pozo MJ, Amigo MC, Alva M, Esteva-Spinetti MH, Pons-Estel BA; GLADEL.

Rheumatology (Oxford). 2012 Jul;51(7):1293-8. doi: 10.1093/rheumatology/ker514. Epub 2012 Mar 2.

29.

Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.

Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, Lozano M, Cid J, Cervera R, Espinosa G.

Autoimmun Rev. 2011 Sep;10(11):679-84. doi: 10.1016/j.autrev.2011.04.028. Epub 2011 May 1. Review.

PMID:
21569864
30.

Epidemiology and management of refractory lupus nephritis.

Pons-Estel GJ, Serrano R, Plasín MA, Espinosa G, Cervera R.

Autoimmun Rev. 2011 Sep;10(11):655-63. doi: 10.1016/j.autrev.2011.04.032. Epub 2011 May 1. Review.

PMID:
21565286
31.

US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV).

Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM.

Ann Rheum Dis. 2011 Feb;70(2):393-4. doi: 10.1136/ard.2010.131482. Epub 2010 Jul 13. No abstract available.

32.

Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort.

Pons-Estel GJ, Alarcón GS, González LA, Zhang J, Vilá LM, Reveille JD, McGwin G Jr; Lumina Study Group.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):393-400. doi: 10.1002/acr.20097.

33.

Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution.

Burgos PI, Perkins EL, Pons-Estel GJ, Kendrick SA, Liu JM, Kendrick WT, Cook WJ, Julian BA, Alarcón GS, Kew CE 2nd.

Arthritis Rheum. 2009 Sep;60(9):2757-66. doi: 10.1002/art.24776.

34.

Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort.

González LA, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS; LUMINA study group.

Lupus. 2009 Aug;18(9):822-30. doi: 10.1177/0961203309104392.

35.

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort.

Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, Reveille JD, Vilá LM; Lumina Study Group.

Arthritis Rheum. 2009 Jun 15;61(6):830-9. doi: 10.1002/art.24538.

36.

Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort.

Pons-Estel GJ, González LA, Zhang J, Burgos PI, Reveille JD, Vilá LM, Alarcón GS.

Rheumatology (Oxford). 2009 Jul;48(7):817-22. doi: 10.1093/rheumatology/kep102. Epub 2009 May 19.

37.

Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort.

Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS.

Rheumatology (Oxford). 2009 May;48(5):542-5. doi: 10.1093/rheumatology/kep012. Epub 2009 Feb 20.

38.

Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII).

González LA, Pons-Estel GJ, Zhang JS, McGwin G Jr, Roseman J, Reveille JD, Vilá LM, Alarcón GS; LUMINA Study Group.

Lupus. 2009 Feb;18(2):184-6. doi: 10.1177/0961203308098988. No abstract available.

39.

Understanding the epidemiology and progression of systemic lupus erythematosus.

Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS.

Semin Arthritis Rheum. 2010 Feb;39(4):257-68. doi: 10.1016/j.semarthrit.2008.10.007. Epub 2009 Jan 10. Review.

40.

Predictors of premature gonadal failure in patients with systemic lupus erythematosus. Results from LUMINA, a multiethnic US cohort (LUMINA LVIII).

González LA, McGwin G Jr, Durán S, Pons-Estel GJ, Apte M, Vilá LM, Reveille JD, Alarcón GS; LUMINA Study Group.

Ann Rheum Dis. 2008 Aug;67(8):1170-3. doi: 10.1136/ard.2007.083436. Epub 2008 Feb 25.

PMID:
18299303

Supplemental Content

Loading ...
Support Center